Management of chronic obstructive pulmonary disease in Asia and Africa

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 2, 2004, Pages 159-170

  Chan Yeung, Moira ^a   Ait Khaled N ^b   White, N ^c   Tsang, K W ^a   Tan, W C ^d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chronic obstructive pulmonary disease; Developing countries; Management

Indexed keywords

CORTICOSTEROID;

AFRICA; ASIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CULTURAL FACTOR; DEVELOPING COUNTRY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INDUSTRIALIZATION; LUNG INFECTION; LUNG TUBERCULOSIS; PATHOGENESIS; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SMOKING CESSATION; SOCIOECONOMICS; SPIROMETER; SPIROMETRY; TOBACCO; TREATMENT PLANNING;

AFRICA; ASIA; COMPREHENSIVE HEALTH CARE; DEVELOPING COUNTRIES; HUMANS; PRACTICE GUIDELINES; PROGRAM EVALUATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 2442419914     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Murray C J L, Lopez A D. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Geneva, Switzerland: World Health Organization, Harvard School of Public Health, World Bank Publication, Summary, 1996.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO report. Publication N° 2701. Bethesda, MD: NIH, April 2001.
3. Siafakas N M, Vermeire P, Pride N B, et al. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
4. American Thoracic Society statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (Suppl): S77-S120.
5. Guidelines for the management of chronic obstructive pulmonary disease. The Thoracic Society of Australia and New Zealand. Mod Med Aust 1995; 38: 132-146.
6. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (Suppl): S1-S28.
7. Mok T, Tsang K, eds. Current management of COPD. Hong Kong: Hong Kong Lung Foundation Ltd, 1999.
8. Chinese Guidelines on COPD and Asthma. Beijing, China: Chinese Society of Respiratory Diseases, Chinese Medical Association, 1998.
9. Working Group of the South African Pulmonology Society. Guidelines for the management of chronic obstructive pulmonary disease. S Afr Med J 1998; 88: 999-1010.
10. Oussedik O N, Aït-Khaled N, Boulahbal M, Chaulet P, Larbaoui D. Proposals for a case management strategy regarding non-specific chronic broncho-pneumopathies in Algeria. Bull Int Union Tuberc Lung Dis 1986; 61(4): 39-40.
11. Ait-Khaled N, Enarson D A, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ 2001; 79: 971-979.
12. Aït-Khaled N. Oxygénothérapie au long cours. Projet pilote du Laboratoire d'Exploration Fonctionnelle Repiratoire de Beni-Messous, Alger, Algérie. Marrakech, Maroc: Congrès International de Langue Française, 20-23 Juin 1993.
13. Mekideche D, Baough L, Ouagueni D, Zidouni N. Stratégie de prise en charge des BPCO en pratique de routine. Annaba, Algérie: Journées de la Fédération Maghrébine des Maladies Respiratoires, 1998.
14. Saadoun R. Recherche des critères cliniques et fonctionnels d'identification des bronchopathies chroniques applicables dans une consultation extra-hospitalière en Algérie. Thèse de Doctorat en Sciences Médicales. Faculté de Médecine, Alger. Algérie, 1991.
15. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
16. Quanjer P T J, Cotes J E, Pedersen R, Peslin R, Yernault J C. Lung volumes and forced ventilatory flows: report of a working party, standardization of lung function tests. European Community for Steel and Coal-Official statement of the European Respiratory Society. Eur Respir J 1993; 6 (Suppl): 5-40.
17. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. ATS statement. Am Rev Respir Dis 1991; 144: 1202-1218.
18. Badgett R G, Tanaka D J, Hunt D K, et al. The clinical evaluation for diagnosing obstructive airways disease in high-risk patients. Chest 1994; 106: 1427-1431.
19. Loveridage B, West P, Kryger M H, Anthonisen N R. Alteration in breathing pattern with progression of chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 134: 930-934.
20. Kresten S, Chapman K R. Physician perceptions and management of COPD. Chest 1993; 104: 254-258.
21. American Thoracic Society Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (Suppl): S78-S121.
22. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive lung disease? Am J Respir Crit Care Med 2002; 166: 329-332.
23. Chan-Yeung M, Aït-Khaled N, White N, Ip M S, Tan W C. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 2004; 8: 2-14.
24. American Thoracic Society. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
25. Mahler D A, Matthaway A, Synder P E, et al. Sustained release theophylline reduces dyspnoea in non-reversible obstructive airway disease. BMJ 1988; 297: 1506-1510.
26. Sandralee A, Blosser M D, Steven L, et al. Is an anticholinergic agent superior to a b2 agonist in improving dyspnoea DNA exercise limitation in COPD? Chest 1995; 108: 730-735.
27. Jenkins S C, Heaton R W, Fulton T J, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987; 91: 804-807.
28. Hughes J A, Tobin M J, Bellamy D, et al. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982; 36: 607-670.
29. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-405.
30. Guyatt G H, Townsend M, Pugsley S O, et al. Bronchodilators in chronic airflow limitation. Effects on airway function, exercise capacity and quality of life. Am Rev Respir Dis 1987; 135: 1069-1074.
31. Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
32. Murciano D, Auclair M H, Parlente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-1525.
33. McKay S E, Howie C A. Thonson A H, Whitting B, Addis G J. Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary disease. Thorax 1993; 48: 227-232.
34. Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-641.
35. Taylor D.R, Buick B, Kinney C, Lowry R C, McDevitt D G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible airflow limitation. Am Rev Respir Dis 1985; 131: 747-751.
36. Cazzola M, Donner C F, Matera M G. Long acting β-2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999; 54: 730-736.
37. Teramoto S. Effect of sustained release of theophylline on pulmonary physiologic function in elderly patients with chronic obstructive pulmonary disease [Japanese]. Nippon Ronen Igakkai Zasshi 2002; 39: 414-418.
38. Jeong C S, Hwang S C, Jones D W, Ryu H S, Sohn K, Sands C D. Theophylline disposition in Korean patients with congestive heart failure. Ann Pharmacother 1994; 28: 396-401.
39. Rojanasthien N, Kovjiriyapan K, Manorot M, Pothirat C. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Asian Pac J Allergy Immunol 2001; 19: 69-78.
40. Chan K W, Lee H S, Ti T Y, Tan T H, Feng P H. A comparative study of the use of choline theophyllinate and a sustained-release theophylline in adults with chronic asthma. Ann Acad Med Singapore 1985; 14: 470-474.
41. Pang J A, Zhang Y G, Swaminathan R. The pharmacokinetics and efficacy of slow-release theophylline with asymmetric dosing in asthmatic Chinese. Chest 1988; 93: 785-789.
42. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-138.
43. Management Sciences for Health. International Drug Price Indicator Guide, 1998. Boston, MA: MSH, 1998.
44. Dictionnaire Vidal. Issy les Moulineaux, France: Editions Vidal, 1999.
45. Ulrik C S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single-centre randomised, double blind placebo controlled crossover study. Thorax 1995; 50: 750-754.
46. Grove A, Lipworth B J, Reid P, Smith R P, Ramage L, Ingram C G. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive disease. Thorax 1996; 51: 689-693.
47. Tan W C. Chronic obstructive pulmonary disease: pharmacological treatment. In: Respiratory Disease-an Asian perspective. Hong Kong: Hong Kong University Press, 2003: In press.
48. Aït-Khaled N, Enarson D. Management of asthma in adults. Guide for Low Income Countries. Paris, France: IUATLD, 1996.
49. Pauwels R A, Lofdahl C G, Laitinen L A, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1948-1953.
50. Vestbo J, Sorensen T, Lange P, et al. Long term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-1823.
51. Burge P S, Calverley P M, Jones P W, et al. Randomised, double-blind, placebo-controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
52. The Lung Health Study Research Group. Effect of inhaled triamsinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
53. Asia-Pacific COPD Round Table Group. GOLD strategy for the diagnosis, management and prevention of COPD. An Asian Pacific perspective. Respirology in press.
54. Poole P J, Black P N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000; 2. Available on URL: www.update-software.com or www.updatusa.com
55. Anthonisen N R, Manfreda J, Warren C P, Hershfield E S, Harding G K, Nelson N A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
56. Thompson W H, Nielson C P, Carvalho P, et al. Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-412.
57. Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456-460.
58. Niewoehner D E, Erbland M L, Deupree R H, et al. Effect of systemic glucocorticosteroids on exacerbations of chronic obstructive pulmonary disease. Dept of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947.
59. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
60. Framework Convention on Tobacco Control. Technical Briefing Series. WHO/NCD/TF1/99.1-7. Geneva, Switzerland: WHO, 1999.
61. Slama K. Tobacco control and prevention. A guide for low income countries. Paris, France: International Union Against Tuberculosis and Lung Disease, 1998.